MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.260
+0.035 (2.86%)
Oct 10, 2025, 10:57 AM EDT - Market open
MediciNova Employees
MediciNova had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$10,354
Profits / Employee
-$908,626
Market Cap
61.80M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 13 | 0 | - |
Dec 31, 2023 | 13 | 0 | - |
Dec 31, 2022 | 13 | 2 | 18.18% |
Dec 31, 2021 | 11 | 2 | 22.22% |
Dec 31, 2020 | 9 | 1 | 12.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MNOV News
- 4 days ago - MediciNova to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire
- 4 weeks ago - MediciNova Provides Shareholder Update on Key Developments - GlobeNewsWire
- 5 weeks ago - MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 weeks ago - MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial - GlobeNewsWire
- 2 months ago - MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million - GlobeNewsWire
- 2 months ago - MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials - GlobeNewsWire
- 6 months ago - MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - GlobeNewsWire
- 6 months ago - First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients - GlobeNewsWire